Royal Bank of Canada Decreases Stake in Incyte Corporation $INCY

Royal Bank of Canada lowered its position in shares of Incyte Corporation (NASDAQ:INCY - Free Report) by 5.6% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,054,123 shares of the biopharmaceutical company's stock after selling 62,259 shares during the quarter. Royal Bank of Canada owned 0.53% of Incyte worth $99,212,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently modified their holdings of INCY. Elyxium Wealth LLC purchased a new stake in shares of Incyte during the fourth quarter valued at approximately $28,000. Smithfield Trust Co lifted its holdings in Incyte by 135.0% during the fourth quarter. Smithfield Trust Co now owns 282 shares of the biopharmaceutical company's stock worth $28,000 after acquiring an additional 162 shares during the period. MUFG Securities EMEA plc purchased a new position in Incyte in the second quarter worth $32,000. CYBER HORNET ETFs LLC purchased a new position in Incyte in the second quarter worth $33,000. Finally, Leonteq Securities AG bought a new position in Incyte in the 4th quarter valued at $35,000. Hedge funds and other institutional investors own 96.97% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the company. Barclays raised their target price on Incyte from $134.00 to $139.00 and gave the company an "overweight" rating in a research report on Wednesday. Oppenheimer reissued a "market perform" rating and issued a $120.00 price target on shares of Incyte in a report on Tuesday. BMO Capital Markets increased their price target on shares of Incyte from $112.00 to $130.00 and gave the company a "market perform" rating in a research report on Wednesday. Truist Financial raised their price objective on shares of Incyte from $103.00 to $105.00 and gave the stock a "hold" rating in a report on Monday, June 22nd. Finally, Weiss Ratings raised shares of Incyte from a "buy (b-)" rating to a "buy (b)" rating in a research report on Wednesday. Eight equities research analysts have rated the stock with a Buy rating and fourteen have issued a Hold rating to the company. According to data from MarketBeat.com, Incyte has an average rating of "Hold" and a consensus price target of $117.74.

Incyte Price Performance

NASDAQ:INCY opened at $119.52 on Friday. The business has a fifty day simple moving average of $109.54 and a two-hundred day simple moving average of $102.24. Incyte Corporation has a 1 year low of $73.81 and a 1 year high of $132.60. The company has a market capitalization of $24.23 billion, a P/E ratio of 15.23, a P/E/G ratio of 1.60 and a beta of 0.76.

Incyte (NASDAQ:INCY - Get Free Report) last issued its earnings results on Tuesday, July 28th. The biopharmaceutical company reported $3.09 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.15 by $0.94. Incyte had a return on equity of 29.93% and a net margin of 27.71%.The firm had revenue of $1.67 billion for the quarter, compared to analyst estimates of $1.50 billion. During the same period in the previous year, the company posted $1.57 earnings per share. The business's revenue was up 37.7% on a year-over-year basis. As a group, analysts anticipate that Incyte Corporation will post 6.38 earnings per share for the current year.

Incyte Profile

Incyte Corporation is a Wilmington, Delaware–based biopharmaceutical company focused on the discovery, development and commercialization of novel therapies in oncology and inflammation. Since its founding in 2002, Incyte has grown from a small research organization into a global enterprise, advancing a portfolio of internally developed and partnered assets. The company's research and development efforts center on small-molecule drugs and biologics that modulate critical signaling pathways implicated in cancer, autoimmune disorders and rare diseases.

The company's flagship product is Jakafi® (ruxolitinib), a Janus kinase (JAK) inhibitor approved for the treatment of myelofibrosis and polycythemia vera.

Want to see what other hedge funds are holding INCY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Incyte Corporation (NASDAQ:INCY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.